CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Ubiquinol +1 moredrug
Likely dose
Ubiquinol 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02934555
NCT02934555Phase 2Completed
CompareCT.gov

Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest

Beth Israel Deaconess Medical Center·interventional·Posted Oct 17, 2016·Updated Feb 15, 2021

In Brief

A Phase 2 clinical trial evaluating Ubiquinol and Ensure for Cardiac Arrest. Completed, enrolled 48 participants across 1 site.

Detailed Summary

To study the effects of ubiquinol as a "metabolic resuscitator" in post-cardiac arrest.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Arrest
CountriesUnited States
CollaboratorsKaneka Medical America LLC

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 17, 2016
Enrollment StartMar 1, 2016
Primary CompletionMay 25, 2019
Study CompletionJun 2, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.7 years ago

Interventions

Ubiquinoldrug

300 mg Ubiquinol (3 mL liquid Ubiquinol).

Ensuredietary

50 mL Ensure